8-K: ALX Oncology Reports Positive Phase 2 Trial Results and Third Quarter 2024 Financials, CFO Resigns

ALX Oncology announced positive topline data from its ASPEN-06 Phase 2 trial, along with its third quarter 2024 financial results, and the resignation of its CFO.

Summary

• ALX Oncology reported its third quarter 2024 financial results, highlighting a net loss of $30.7 million, or $0.58 per share, compared to a net loss of $51.0 million, or $1.24 per share, in the same period last year.
• The company's research and development expenses decreased to $26.5 million from $45.8 million year-over-year, primarily due to lower clinical trial material manufacturing costs.
• General and administrative expenses also decreased to $6.1 million from $7.5 million year-over-year, mainly due to lower stock-based compensation and accounting consulting costs.
• The company's cash, cash equivalents, and investments totaled $162.6 million as of September 30, 2024, which they believe is sufficient to fund operations well into Q1 2026.
• Topline data from the ASPEN-06 Phase 2 trial showed that evorpacept, in combination with other therapies, achieved a 40.3% overall response rate (ORR) compared to 26.6% in the control arm, with a median duration of response of 15.7 months versus 7.6 months.
• In a pre-specified population with fresh HER2-positive biopsies, the ORR was even higher at 54.8% compared to 23.1% in the control arm.
• The company also commenced patient dosing in a Sanofi-partnered study investigating evorpacept in multiple myeloma.
• The company appointed Alan Sandler, M.D. to the Board of Directors.
• Peter Garcia, the Chief Financial Officer, resigned effective November 8, 2024, and Shelly Pinto was appointed as interim CFO.

Sentiment

Score: 8

Explanation: The document presents positive clinical trial results and a strong cash position, but the CFO resignation and ongoing losses temper the overall sentiment. The clinical results are very promising.

Positives

• The ASPEN-06 Phase 2 trial showed a significant improvement in tumor response with evorpacept, demonstrating a durable clinical benefit and a well-tolerated safety profile.
• The company's cash position is strong, with sufficient funds to support operations well into Q1 2026.
• Research and development expenses decreased significantly, indicating improved cost management.
• The appointment of Alan Sandler, M.D. to the Board of Directors brings valuable expertise in oncology and drug development.
• The company is advancing multiple clinical trials for evorpacept across various cancer indications.

Negatives

• The company reported a net loss of $30.7 million for the third quarter of 2024.
• Peter Garcia, the Chief Financial Officer, resigned effective November 8, 2024, creating a leadership transition.
• Secondary endpoints of PFS and OS in the ASPEN-06 trial were immature at the time of analysis.

Risks

• The company is still in the clinical stage and faces risks associated with drug development, including clinical trial failures and regulatory hurdles.
• The company is dependent on the success of its lead candidate, evorpacept.
• The resignation of the CFO could create uncertainty and potential disruption in financial management.
• The company's future success depends on its ability to raise additional capital if needed.

Future Outlook

The company anticipates achieving several additional clinical milestones in the near-term that could advance evorpacept towards being a best-in-class, combinable therapeutic across a wide range of cancer types. They also believe their current cash position is sufficient to fund operations well into Q1 2026.

Management Comments

• Jason Lettmann, Chief Executive Officer of ALX Oncology, stated that the ASPEN-06 Phase 2 trial results provided further validation for evorpacepts novel mechanism of action and their robust evorpacept clinical program.
• The company believes its cash, cash equivalents and investments are sufficient to fund planned operations well into Q1 2026.

Industry Context

The positive results from the ASPEN-06 trial position ALX Oncology as a potential leader in the CD47-blocking agent space, which is a competitive area in immuno-oncology. The company's focus on combination therapies aligns with current trends in cancer treatment.

Comparison to Industry Standards

• The 40.3% ORR in the ASPEN-06 trial is competitive with other targeted therapies in HER2-positive gastric cancer, such as trastuzumab and ramucirumab combinations, which typically show ORRs in the 20-30% range.
• The 15.7-month median duration of response is a significant improvement compared to the 7.6 months in the control arm, suggesting a more durable benefit than standard treatments.
• The 54.8% ORR in the pre-specified population with fresh HER2-positive biopsies is particularly promising and could position evorpacept as a preferred option in this patient subgroup.
• Companies like Forty Seven Inc. (acquired by Gilead) and Trillium Therapeutics (acquired by Pfizer) have also been developing CD47-blocking agents, but ALX Oncology's results in a randomized trial are a notable advancement.
• The company's cash runway into Q1 2026 is relatively strong compared to other clinical-stage biotech companies, providing financial stability for ongoing development.

Management Changes

Stakeholder Impact

• Shareholders may react positively to the promising clinical trial results and the company's strong cash position.
• Employees may experience some uncertainty due to the CFO's resignation, but the appointment of an interim CFO provides stability.
• Patients with cancer may benefit from the development of evorpacept as a potential new treatment option.
• The company's financial stability and clinical progress may positively impact its relationships with suppliers and creditors.

Next Steps

• The company will present results from a Phase 1b/2 combination trial at the San Antonio Breast Cancer Symposium on December 12, 2024.
• Updated results of the ASPEN-06 Phase 2 clinical trial are expected in the first half of 2025.
• Topline results from the ASPEN-03 and ASPEN-04 trials are expected in the first half of 2025.
• Updated results from the ASPEN-07 trial are expected in the first half of 2025.
• The company plans to initiate a Phase 3 registrational randomized clinical trial for evorpacept in mid-2025.
• Topline results from a Phase 1b I-SPY TRIAL with ENHERTU are expected in the second half of 2025.

Key Dates

Keywords

evorpacept, oncology, cancer, clinical trial, CD47 blocker, immunotherapy, financial results, biotechnology, HER2-positive, gastric cancer, multiple myeloma, research and development